XML 43 R22.htm IDEA: XBRL DOCUMENT v3.25.1

CONCENTRATIONS	12 Months Ended
	Dec. 31, 2024
CONCENTRATIONS [Abstract]
CONCENTRATIONS	16. CONCENTRATIONS Financial instruments that potentially subject the Company to concentrations of credit risk consist of accounts receivable. At December 31, 2024, three customers accounted for approximately 91% of the Company’s consolidated accounts receivable. At December 31, 2023, five customers accounted for approximately 98% of the Company’s consolidated accounts receivable. For the years ended December 31, 2024 and 2023, two customers accounted for approximately 72% of the Company’s consolidated revenues. For the year ended December 31, 2022, two customers accounted for approximately 74% of the Company’s consolidated revenues. Revenues for both of these customers are attributable to the ADMA BioManufacturing business segment. There were no customers attributable to the Plasma Collections Center whose revenues exceeded 10% of the Company’s consolidated revenues.

X

- Definition

The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 275
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/275/tableOfContent

+ Details

Name:	us-gaap_ConcentrationRiskDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration